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Abstract
Background
Depression and psychosis are common comorbidities that significantly affects the quality of life
and disease outcomes in Parkinson’s disease (PD) patients.
Objective
The aim of this study was to analyze and discern the differences in the hospitalization
outcomes, comorbidities, and utilization of deep brain stimulation (DBS) in PD patients with
comorbid depression and comorbid psychosis.
Methods
We used the Nationwide Inpatient Sample (2010-2014) and identified PD as a primary diagnosis
(N = 62,783), and depression (N = 11,358) and psychosis (N = 2,475) as co-diagnosis using the
International Classification of Diseases, Ninth Revision (ICD-9) codes. Pearson’s chi-square
test and independent-sample t-test were used for categorical data and continuous data,
respectively.
Results
White male, older age, and comorbid psychosis were significantly associated with higher odds
of having major severity of illness in PD inpatients. The mean length of stay (LOS) was higher
in PD patients with psychosis compared to PD with depression (7.32 days vs. 4.23 days; P <
0.001), though the mean total charges of hospitalization were lower in psychosis ($31,240 vs.
$38,581; P < 0.001). Utilization of DBS was lower in PD patients with psychosis versus with
depression (3.9% vs. 24.3%; P < 0.001).
Conclusion
Psychiatric comorbidities are prevalent in PD patients and are associated with more disease
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severity, impaired quality of life, and increased use of healthcare resources (higher LOS and
cost). They should be considered an integral part of the disease, and a multidisciplinary
approach to managing this disease is crucial to improve the health-related quality of life of PD
patients.
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Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that destroys dopamine-
producing neurons and results in a movement disorder with motor and non-motor symptoms.
It is estimated that about 930,000 people will have PD by 2020 and a possible projection of 1.2
million people by 2030 [1]. These numbers are as alarming as the economic burden estimated at
14.4 billion dollars in 2010, approximately $8.1 billion higher than in non-PD individuals
[2]. Not only does PD manifest as motor symptoms, but its non-motor symptoms reflect the
advanced stage of the disease of which neuropsychiatric symptoms were the strongest
predictor of nursing home admissions [3].
Multiple studies have been done on psychiatric comorbidities in PD patients. Some risk factors
for depression in PD patients are severity and duration of illness, presence of tremors,
bradykinesia or motor disability, and associated anxiety or psychosis [4]. On the other hand,
psychosis is not a primary symptom in PD patients, but its risk increases with comorbid
depression, dementia, and longer duration of illness [4]. Depression in PD patients is also
underdiagnosed and negatively impacts the course of the disease [5]. PD with a higher
prevalence of psychiatric comorbidities is associated with poor health-related quality of life and
higher treatment costs [4,6]. The clear pathophysiology behind psychiatric comorbidities and
PD remains unclear, but prompt diagnosis and treatment can cure these conditions [7].
We conducted a national study using the nationwide inpatient sample (NIS) data to evaluate 1)
differences in demographics and hospital outcomes by psychiatric comorbidities (depression
and psychosis) and 2) impact of psychiatric comorbidities on the severity of illness and adverse
discharges to skilled nursing facilities or intermediate nursing facilities (SNF/INF).
Materials And Methods
Data source
A retrospective study was conducted using the Healthcare Cost and Utilization Project's (HCUP)
NIS data from 2010 to 2014 [8]. The NIS database is considered to determine patterns in
demographics and hospital outcomes. It is the largest inpatient database which covers 4,411
hospitals from 45 states in the United States [8]. To protect the privacy of individual patients,
physicians, and hospitals, the state and hospital identifiers are de-identified [8]. We were not
required to obtain an institutional review board permission to conduct a study on publicly
available de-identified data.
Inclusion criteria
We included adult patients (age ≥40 years) with a principal diagnosis of PD based on
the international classification of diseases, ninth revision (ICD-9) diagnosis code 332.0 [6].
These sample populations (N = 62,783) were grouped by the presence of comorbid depression
(N = 11,358), psychosis (N = 2,475), and non-depression/psychosis group (N = 48950). The ICD-9
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diagnoses codes were used to identify co-diagnoses of depression (300.4, 301.12, 309.00, 309.1,
or 311) and psychosis (295.00-298.9, 299.10, or 299.11) [6].
Variables of interest
The demographic variables included in this study were age, sex, race, and median household
income [9]. To measure the differences in-hospital outcomes in PD patients by the presence of
depression and psychosis, the following variables were included: severity of illness that
measures the loss of functions, length of stay (LOS), total charges, and utilization of deep brain
stimulation (DBS, ICD-9 procedure code 02.93) [9]. In the NIS, LOS means the number of nights
the patient remained in the hospital for the principal diagnosis. Total charges during PD
hospitalization do not include professional fees and non-covered charges [9].
Statistical analyses
We used descriptive statistics and linear-by-linear association test for categorical data and
independent sample t-test for the continuous data to measure the differences in demographics
and hospital outcomes. We used discharge weight, which is given in the NIS, to obtain a
national representation of the sample population [9]. Differences in comorbidities were
quantified using chi-square tests. We used a binomial logistic regression model to evaluate the
odds ratio (OR) and 95% confidence interval (CI) for major or extreme severity of illness in PD
inpatients. The regression model was adjusted for age, sex, race, and median household
income. A P-value <0.05 was used to determine the statistical significance of the test result. All
statistical analyses were done using statistical package for the social sciences (SPSS) version 25
(IBM Corp., Armonk, New York).
Results
We analyzed a total of 62,783 PD inpatients. Out of these, the prevalence of comorbid
depression and psychosis was 18.1% and 3.9%, respectively. Majority of total inpatients were
elderly patients (60-79 years, 59.2%). As compared to total inpatients (37.2% females),
depression and psychosis were prevalent in females (44.9% and 41.8%). White constituted
about four-fifths of the total PD inpatients, and compared to the total, rate of PD with
depression was higher in White and PD with psychosis was higher in Black. Also, a higher
proportion of PD with psychosis inpatients was from low-income families below 25th percentile
compared to PD with depression and total inpatients (28.6% vs. 21.9% and 22.4%, respectively),
as shown in Table 1.
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Variable Depression (%) Psychosis (%) Total (%) P-value
Inpatients 11358 2475 62783 -
Age at admission, in years
Mean age (Standard deviation) 71.3 (10.42) 70.1 (10.51) 72.2 (10.66) <0.001
40 – 59 14.3 15.3 12.9
<0.00160 – 79 62.2 65.2 59.2
+80 23.6 19.5 27.9
Sex
Male 55.1 58.2 62.9
<0.001
Female 44.9 41.8 37.2
Race
White 84.9 76.0 80.6
<0.001
Black 4.3 8.7 6.5
Hispanic 6.4 7.8 6.8
Other 4.4 7.5 6.1
Median household income, in percentile
0–25th 21.9 28.6 22.4
<0.001
26th–50th 25.5 23.9 25.2
51st–75th 26.6 24.2 25.8
76th–100th 26.0 23.3 26.6
Severity of illness, in loss of function
Minor 32.1 21.2 33.8
<0.001Moderate 47.7 52.6 44.2
Major 20.2 26.2 22.0
Deep brain stimulation (DBS) utilization 24.3 3.9 26.1 <0.001
TABLE 1: Characteristics of Parkinson’s disease inpatients by psychiatric
comorbidities
Moderate to major severity of illness and loss of function was seen in a higher proportion of PD
with psychosis inpatients, as shown in Table 1. With advancing age, the odd of association
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increases with older age patients (>80 years) having 5.3-folds higher odds of major severity of
illness (95% CI, 4.830 to 5.840). Male has a marginally higher odds for major severity compared
to females. Hispanics are 1.65-fold higher odds (95% CI, 1.528 to 1.781) for major severity
compared to Whites, as shown in Table 2.
Variable Odds Ratio
95% confidence interval
P-value
Lower Upper
Age at admission, in years
40–59 Reference
60–79 2.51 2.290 2.747 <0.001
+80 5.31 4.830 5.840 <0.001
Sex
Male 1.19 1.138 1.240 <0.001
Female Reference
Race
White Reference
Black 1.65 1.528 1.781 <0.001
Hispanic 1.04 0.952 1.128 0.406
Other 0.99 0.909 1.085 0.881
Median household income, in percentile
0–25th Reference
26th–50th 0.98 0.925 1.042 0.547
51st–75th 1.00 0.946 1.065 0.904
76th–100th 1.06 0.995 1.118 0.075
Psychiatric comorbidities
Depression 0.96 0.91 1.01 0.145
Psychosis 1.38 1.252 1.524 <0.001
TABLE 2: Odds of association for major severity of illness in Parkinson’s disease
inpatients
The logistic regression model was controlled for demographic confounders, and we found a
statistically significant higher odds of association of 1.4-fold (95% CI, 1.252 to 1.524) between
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major severity of illness in PD inpatients and comorbid psychosis.
The utilization of DBS was very low in psychosis inpatients compared to PD with depression
and total inpatients (3.9% vs. 24.3% and 26.1%, respectively). PD with psychosis inpatients had
a statistically significant (P <0.001) longer mean LOS of 7.3 days (±15.33) compared to total (4.1
days ± 8.7) and PD with depression (4.2 days ± 9.83). However, these inpatients with psychosis
had a statistically significant (P <0.001) lower mean total charges ($31,240 ± 36,926) during PD
hospitalization compared to total inpatients ($39,688 ± 43,902) and PD with depression
($38,581 ± 40,137).
Discussion
We found that comorbid depression (18.1%) was more prevalent among hospitalized PD
patients compared to comorbid psychosis (3.9%). Majority of the PD inpatients were males
(62.9%) and Whites (80.6%) and had a moderate loss of bodily functions (44.2%). Major severity
of illness in PD inpatients was seen in patients with comorbid psychosis (1.4 times higher) with
significantly longer mean LOS (7.32 days) compared to those with comorbid depression (4.23
days). DBS utilization was significantly higher in PD patients with comorbid depression (24.3%)
versus comorbid psychosis (3.9%).
Psychiatric illnesses are prevalent in PD and this may significantly impact the patient’s
morbidity and quality of life [10-12]. Several studies have established the association between
depression and PD [13-15]. In our cross-sectional study, we found that comorbid depression is
prevalent (18.1%) among hospitalized patients with PD. This correlates with previous literature
showing a high prevalence of comorbid depression among adults with PD. In a systematic
review and meta-analysis conducted by Goodarzi et al., the incidence of depression among PD
patients was reported to be 22.9% [15]. The prevalence of psychosis in PD has been challenging
to determine, and many past studies indicate varying results. In a longitudinal survey of Forsaa
et al., 230 PD patients were followed for twelve years, and 60% had reported psychotic
symptoms [16]. On the contrary, a cross-sectional study involving 236 PD patients found that
13% reported psychotic symptoms [17].
PD is a neurodegenerative disease, and its incidence increases with age with advanced age
being a risk factor for developing PD [18]. Fifty-nine percent PD inpatients were elder patients
(60-79 years) and compared to the overall total, a higher rate of comorbid depression (62.2%)
and psychosis (65.2%) was seen in this age group. Elder PD patients had a higher odd (2.5 times
in 60-79 years, and 5.3 times in +80 years) of major severity of illness with loss of bodily
functions compared to middle-age (40-59 years) patients. Given the progressive nature of the
disease, and advancing age associated with comorbidities, and poor health outcomes, including
mortality, maybe the reason for worsening of functionality in older age PD patients.
The prevalence of PD was higher in males (62.9%), which was also seen in past studies [18-20].
Shulman et al. found that the incidence of PD is lower in postmenopausal women and postulate
that estrogen may play a protective role [21]. Compared to the overall total (37.2%), comorbid
depression (44.9%) and psychosis (41.8%) was seen at a higher rate in females [22-24]. We found
that men with PD have a marginally higher risk of major severity of illness compared to
females. Lubomski et al. reported that men have a lower quality of life in activities of daily
living (ADL), cognition, and communication sub-scales [24].
On the contrary, Georgiev et al. found that women with PD show better cognitive abilities and
outperform men in verbal cognitive tasks but show more pain symptoms, and experience more
depression [25]. The hospitalized Black PD patients had 1.7-fold higher odds of major severity
of illness compared to the White with PD. The racial differences in mortality and disease
incidence among PD patients exist [26-27]. Willis et al. found that Black patients with PD had a
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higher likelihood of death during the six-year study period compared to Whites with PD [27].
Our study is the first to highlight the racial difference in terms of the severity of illness among
hospitalized PD patients in the US.
Furthermore, we observed that the LOS and total charges of hospitalization for PD differs
among comorbidities (depression and psychosis). PD patients with comorbid psychosis had a
longer mean LOS (7.3 days) compared to total PD inpatients (4.0 days) and PD with comorbid
depression (4.2 days). Although PD patients with comorbid psychosis had higher hospitalization
cost compared to the PD inpatient with psychosis, and this discrepancy may be due to the very
low utilization of DBS in PD patients with comorbid psychosis (3.9% vs. 26.1 in total PD
inpatients). In the study by Patel et al., DBS utilization, as well as therapeutic procedures, were
less commonly performed in PD patients with depression in comparison to those without
depression [6].
Our findings contrast with prior studies which found that PD with psychosis resulted in the
more extended length of hospitalization and higher costs of care (including inpatient and long-
term care) [28-29]. Hermanowicz et al. noted that all expenses were higher for PD patients with
comorbid psychosis, with the highest cost differentials found in long-term care, SNF, and
inpatient costs ($10,125 in PD with psychosis vs. $6024 in PD without psychosis) [29].
One of the strengths of our study is that we used the NIS database, which is a nationally
representative sample of patients diagnosed with PD. The large sample size we obtained
ensures that our study is high powered to identify any differences that exist in the subgroups of
patients analyzed. Also, our application of sampling weights to generate estimates of inpatient
outcomes enables extrapolation and generalizability of our results to a much larger population
than the sample studied. Furthermore, this is the first study, to our knowledge, to evaluate and
compare the differences in the impact of comorbid psychosis and comorbid depression in PD
patients regarding hospital outcomes and morbidity. However, the results in our study should
be interpreted with several limitations in mind. Our utilization of inpatient data (and not
patient-level data) as the unit of analysis precludes generalizability for all patients with PD.
Also, given the nature of the database, we did not account for re-hospitalization. Re-
hospitalizations may add to the total disease burden and may help explain some of the
differences in hospitalization costs. Furthermore, we did not adjust for other important
characteristics such as patients' complications and comorbidities, which may affect our results.
Therefore, we recommend that future research should utilize clinical data and employ
longitudinal based designs to evaluate differences in outcomes between PD patients with
psychosis and those with depression.
Conclusions
Our study establishes the negative impact of depression and psychosis in PD concerning
hospitalization-related outcomes including the illness severity, comorbid conditions, LOS and
total charges during hospitalization, and utilization of DBS. The results of our study suggest
that healthcare providers should actively screen for psychiatric comorbidities like depression
and psychosis in patients with PD. These comorbidities are prevalent in the majority of patients
with PD and are associated with more disease severity, impaired quality of life, and increased
use of healthcare resources (higher LOS and cost). Psychiatric comorbidities in PD should be
considered an integral part of the disease, and a multidisciplinary approach to managing this
disease is crucial to improve the overall outcome and the health-related quality of life of PD
patients.
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